Expert Interview
Discussing the Phase 2b trial for demonstrating the effectiveness of combining bimagrumab – a drug designed to combat muscle loss – with a common GLP-1 receptor agonist (RA), semaglutide.
Ticker(s): LLYInstitution: Mayo Clinic
- Endocrinologist and part of the Mayo Clinic Precision Medicine for Obesity program
- Treats over 1000 patients for obesity per year
- Clinical and research focus on understanding obesity's pathophysiology to develop more effective therapeutic interventions, especially for perimenopausal women and breast cancer survivors.
On a scale from 1-10 (10 being extremely excited), how excited are you about the Phase 2b data for bimagrumab?
Added By: nikki_adminHow many patients do you manage for weight loss and obesity?
Added By: nikki_adminWith tirzepatide and clinical development of orforglipron, eloralintide, and Bimagrumab, how do you see the treatment algorithm emerging for these medications if they all are approved?
Added By: pharmaadvisorHow important is it to you that Bimagrumab is eventually studied for CVRM outcomes?
Added By: pharmaadvisorWhat do you think are the most important takeaways from the Phase trial of this asset?
Added By: pharmaadvisorAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
